Change from baseline to week 8* in HDL-SAA and sPLA2 IIA for week 24 ACR20, ACR50 and EULAR good/moderate responders and non-responders (bio-repository population)
| Subgroup | Statistic | ADA 40 mg SC q2w, n=97 | TCZ 8 mg/kg IV q4w, n=87 |
|---|---|---|---|
| HDL-SAA change from baseline to week 8 (mg/L) | |||
| ACR20 responders | |||
| n | 32 | 39 | |
| Median (IQR) | –1.0 (–6.8, 0.55) | –3.3 (10.0, –1.0) | |
| Mean (SD) | –5.8 (12.5) | –10.3 (21.1) | |
| ACR20 non-responders | |||
| n | 30 | 16 | |
| Median (IQR) | –1.1 (–8.7, 1.2) | –3.1 (–12.95, –1.15) | |
| Mean (SD) | –2.9 (12.1) | –7.1 (7.8) | |
| ACR50 responders | |||
| n | 20 | 26 | |
| Median (IQR) | –1.6 (–6.6, 0.25) | –3.3 (–8.6, –1.0) | |
| Mean (SD) | –5.1 (11.2) | –11.8 (25.1) | |
| ACR50 non-responders | |||
| n | 42 | 29 | |
| Median (IQR) | –0.9 (–7.10, 0.7) | –3.2 (–12.8, –1.0) | |
| Mean (SD) | –4.0 (12.9) | –7.2 (8.4) | |
| EULAR good/moderate responders | |||
| n | 36 | 45 | |
| Median (IQR) | –2.8 (–9.05, 0.5) | –3.2 (–10.0, –1.0) | |
| Mean (SD) | –6.2 (12.3) | –9.6 (19.8) | |
| EULAR non-responders | |||
| n | 26 | 10 | |
| Median (IQR) | –0.5 (–5.7, 1.2) | –2.9 (–18.2, –1.3) | |
| Mean (SD) | –1.9 (12.1) | –8.0 (8.9) | |
| sPLA2 IIA change from baseline to week 8 (ng/mL) | |||
| ACR20 responders | |||
| n | 47 | 52 | |
| Median (IQR) | –1.3 (–3.2, 0.7) | –4.8 (–9.5, –1.3) | |
| Mean (SD) | –1.6 (8.3) | –9.5 (14.8) | |
| ACR20 non-responders | |||
| n | 39 | 21 | |
| Median (IQR) | –0.6 (–2.8, 1.9) | –3.1 (–4.9, –1.0) | |
| Mean (SD) | –2.0 (10.2) | –3.7 (2.7) | |
| ACR50 responders | |||
| n | 24 | 36 | |
| Median (IQR) | –1.8 (–2.6, 0.2) | –5.0 (–9.5, –0.95) | |
| Mean (SD) | –1.6 (2.5) | –9.7 (13.9) | |
| ACR50 non-responders | |||
| n | 62 | 37 | |
| Median (IQR) | –1.0 (–3.2, 1.4) | –4.0 (–6.7, –1.5) | |
| Mean (SD) | –1.9 (10.7) | –6.1 (11.5) | |
| EULAR good/moderate responders | |||
| n | 53 | 62 | |
| Median (IQR) | –1.6 (–3.2, 0.7) | –4.7 (–9.1, –1.1) | |
| Mean (SD) | –2.2 (9.8) | –8.7 (13.7) | |
| EULAR non-responders | |||
| n | 33 | 11 | |
| Median (IQR) | –0.2 (–2.1, 1.9) | –2.7 (–6.0, –0.8) | |
| Mean (SD) | –1.2 (8.1) | –3.2 (2.4) | |
n represents number of patients contributing to summary statistics.
The range of data for each parameter is depicted in figure 1.
*Includes only patients with both baseline and week 8 values.
ACR, American College of Rheumatology; ADA, adalimumab; EULAR, European League against Rheumatism; HDL-SAA, high-density lipoprotein-associated serum amyloid-A; IV, intravenous; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; sPLA2 IIA, secretory phospholipase A2 IIA; TCZ, tocilizumab.